Prospective, Multi-center, Single-arm, Observational Study. US FDA 522 Pediatric Post Market Surveillance Study.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

36 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-01-20

Study Completion Date

2025-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The post market surveillance study will employ a prospective, multi-center, single-arm, observational design to capture data on children who undergo CRRT using the Carpediem™ system. Participating clinicians will manage subjects in accordance to their local standard of care practices and decisions on initiating, modifying or discontinuing CRRT are up to the local investigative team's prescription.

A minimum of 10 centers in the United States, that have been trained on the use of the Carpediem™ system, will be invited to participate in the study. After obtaining institutional review board approval and written informed consent from a parent or legally authorized representative (LAR), data from all subjects treated with the Carpediem™ system will be included in the study. A minimum of 35 subjects will be enrolled and sites may be asked to screen and enroll patients for the study for up to 36 months.

Status of subjects discharged from hospital will be collected at 30- and-90 days following hospital discharge by phone interviews in accordance to local standard of care practices, review of in-hospital records or in-clinic visit, as available.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Post-Market Observational Study of Intra-Renal Drug Delivery

NCT00716404

Targeted Renal Therapy

WITHDRAWN

An Open Label Study to Allow Patients Continuous Use of the HemoCare™ Hemodialysis System

NCT04198012

End Stage Renal Disease

COMPLETED NA

Continous Renal Replacement Therapy With the CARPEDIEM® in a French National Cohort of 25 Neonates and Small Infants

NCT05495607

Hypoxic-Ischemic Encephalopathy Sepsis Kidney Diseases +4 more

COMPLETED

Evaluation of Non-Invasive Continuous vs Intermittent BloodPressure Monitors in Maintenance Dialysis (BP Dialysis)

NCT05540457

End Stage Renal Disease End Stage Renal Disease on Dialysis Dialysis Hypotension +1 more

COMPLETED NA

Application of Impedance Threshold Device Technologies to Treat and Prevent Hypotension During Dialysis

NCT00576524

Intradialytic Hypotension End Stage Renal Disease Low Blood Pressure

TERMINATED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The post market surveillance study is designed to capture data in the real-world clinical setting on the use of the Carpediem™ system and will evaluate the safety and performance in children requiring CRRT in the US. Data on survival and the effectiveness of the Carpediem™ system on renal function recovery will be evaluated. A comprehensive evaluation of subjects being treated with Carpediem™ will include, but is not limited to, acuity at hospital/ICU admission and prior to CRRT initiation, Carpediem™ treatment parameters, laboratory data, and requirement for mechanical ventilation and/or inotropic support. Subject status and requirement for renal replacement therapy post hospital discharge will be evaluated at 30- and 90-days.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Kidney Injury Fluid Overload

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Subjects treated with Carpediem system

All patients who receive CRRT with the Carpediem™ system, as prescribed by the investigator, will be offered participation in the post market surveillance study after obtaining parental consent.

Carpediem System

Intervention Type DEVICE

Continuous renal replacement therapy

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Carpediem System

Continuous renal replacement therapy

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Parent or LAR has signed information consent
* Subject weighs between 2.5-10 kg (or 5.5-22 lbs)
* Subject is receiving medical care in an intensive care unit
* Parental or LAR consent to receive full supportive care through aggressive management utilizing all available therapies for a minimum of 96 hours
* Subject has a clinical diagnosis of acute kidney injury per Kidney Disease Improving Global Outcomes (KDIGO) criteria or fluid overload requiring CRRT

Exclusion Criteria

* Subject is not expected to survive 72 hours due to an irreversible medical condition, in the opinion of the investigator
* Subject has irreversible brain damage, in the opinion of the investigator
* Subject is intolerant to anticoagulation, as documented in the medical record
* Subject has a Do Not Attempt Resuscitate (DNAR), Allow Natural Death (AND), withdrawal of care or similar order, or anticipated change in status, in the opinion of the investigator, within the next 7 days
* Subject has pre-existing end-stage renal disease or pre-existing, advanced chronic kidney disease, defined as an estimated Glomerular Filtration Rate (eGRF) \< 30 ml/min/1.73m2
* Subject is currently or has chronically been treated with a circulatory support device (i.e., left ventricular assist device (LVAD)) other than ECMO
* Subject has had prior CRRT treatments using the Carpediem™ system
* Subject is enrolled in clinical trials or being treated with other investigational therapeutic devices or products for acute kidney injury or fluid overload
* Subject has any other medical condition that may confound the study objectives, in the opinion of the investigator

Eligible Sex

ALL

Accepts Healthy Volunteers

No